Clovis Oncology Announces Presentations at 2018 ASCO Annual Meeting

Accepted abstracts highlight additional data from phase 3 ARIEL3
clinical trial, as well as trials in progress presentations of Rubraca
(rucaparib) in multiple solid tumor settings at ASCO

BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that seven
abstracts highlighting progress in the Rubraca preclinical research and
clinical development program will be presented at the 2018 American
Society of Clinical Oncology (ASCO) Annual Meeting taking place June 1-5
in Chicago.

The accepted abstracts include additional data from the phase 3 ARIEL3
clinical trial, as well as summaries of ongoing preclinical research and
multiple clinical trials in which Rubraca is being studied as
monotherapy and in combination in cancer types including ovarian,
bladder, prostate and breast cancers.

“Rubraca has demonstrated its ability to reduce the risk of disease
progression following platinum-based chemotherapy for women with
advanced ovarian cancer, and our team is dedicated to fully exploring
the potential of this molecule as a new treatment option for patients
being treated for other cancer types where PARP inhibitors have shown
encouraging results,” said Patrick J. Mahaffy, President and CEO of
Clovis Oncology. “We look forward to sharing updates on the progress of
our clinical development program at ASCO 2018.”

The four Clovis Oncology-sponsored abstracts accepted for presentation
at the 2018 ASCO Annual Meeting comprise:

Abstract TPS4592 (Poster 415a) – ATLAS: A phase 2, open-label
study of rucaparib in patients (pts) with locally advanced or metastatic
urothelial carcinoma (mUC).

  • Presenter: Petros Grivas, MD, PhD, University of Washington
  • Session: Genitourinary (Nonprostate) Cancer
  • Date/Time: Saturday, June 2, 8:00 -11:30 a.m. CT
  • Location: Hall A

Abstract 5537 (Poster 264) – Evaluation of rucaparib in
platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts)
with or without residual bulky disease at baseline in the ARIEL3 study.

  • Presenter: Carol Aghajanian, MD, Memorial Sloan Kettering Cancer Center
  • Session: Gynecologic Cancer
  • Date/Time: Monday, June 4, 1:15 -4:45 p.m. CT
  • Location: Hall A

Abstract 5545 (Poster 272) – Exploratory analysis of percentage
of genomic loss of heterozygosity (LOH) in patients with
platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.

  • Presenter: Ana Oaknin, MD, PhD, Vall d’Hebron University Hospital,
    Vall d’Hebron Institute of Oncology (VHIO)
  • Session: Gynecologic Cancer
  • Date/Time: Monday, June 4, 1:15 -4:45 p.m. CT
  • Location: Hall A

Abstract 5582 (Poster 309) – Efficacy and immune modulation of
the tumor microenvironment with the combination of the PARP inhibitor
rucaparib and CD122-biased agonist NKTR-214.

  • Presenter: Andrew Simmons, PhD, Clovis Oncology
  • Session: Gynecologic Cancer
  • Date/Time: Monday, June 4, 1:15 -4:45 p.m. CT
  • Location: Hall A

Additionally, three additional collaborator and investigator sponsored
abstracts investigating Rubraca in metastatic breast and prostate
cancers are also being presented:

Abstract TPS1112 (Poster 187a) – An open-label, phase II study of
rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients
with high genomic loss of heterozygosity.

  • Presenter: Anne Patsouris, Institute of West Cancerology Paul Papin
  • Session: Breast Cancer – Metastatic
  • Date/Time: Saturday, June 2, 8:00-11:30 a.m. CT
  • Location: Hall A

Abstract TPS5095 (Poster 317b) – Phase II trial of rucaparib
(without ADT) in patients with metastatic hormone-sensitive prostate
cancer harboring germline DNA repair gene mutations (TRIUMPH).

  • Presenter: Mark Christopher Markowski, MD, PhD, The Sidney Kimmel
    Comprehensive Cancer Center at Johns Hopkins University
  • Session: Genitourinary (Prostate) Cancer
  • Date/Time: Saturday, June 2, 1:15-4:45 p.m. CT
  • Location: Hall A

Abstract TPS3126 (Poster 327b) – An open-label, phase 2 study of
nivolumab in combination with either rucaparib, docetaxel, or
enzalutamide in men with castration-resistant metastatic prostate cancer
(mCRPC; CheckMate 9KD).

  • Presenter: Karim Fizazi, MD, PhD, Gustave Roussy
  • Session: Developmental Therapeutics—Immunotherapy
  • Date/Time: Monday, June 4, 8:00-11:30 a.m. CT
  • Location: Hall A

Clovis Oncology’s Rubraca posters will be available online at
as of the time they are presented at the meeting.

About Rubraca (rucaparib)

Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3
being developed in ovarian cancer as well as several additional solid
tumor indications. Studies open for enrollment or under consideration
include ovarian, prostate, breast, gastroesophageal, pancreatic, lung
and bladder cancers. Clovis holds worldwide rights for Rubraca.

In the United States, Rubraca is approved for the maintenance treatment
of adult patients with recurrent epithelial ovarian, fallopian tube, or
primary peritoneal cancer who are in a complete or partial response to
platinum-based chemotherapy. Rubraca is also approved in the United
States for the treatment of adult patients with deleterious BRCA
mutation (germline and/or somatic) associated epithelial ovarian,
fallopian tube, or primary peritoneal cancer who have been treated with
two or more chemotherapies, and selected for therapy based on an
FDA-approved companion diagnostic for Rubraca.

Rubraca is an unlicensed medical product outside of the U.S.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer agents
in the U.S., Europe and additional international markets. Clovis
Oncology targets development programs at specific subsets of cancer
populations, and simultaneously develops, with partners, diagnostic
tools intended to direct a compound in development to the population
that is most likely to benefit from its use. Clovis Oncology is
headquartered in Boulder, Colorado, and has additional offices in San
Francisco, California and Cambridge, UK. Please visit
for more information.

To the extent that statements contained in this press release are not
descriptions of historical facts regarding Clovis Oncology, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Examples of
forward-looking statements contained in this press release include,
among others, statements regarding the timing and pace of commencement
of and enrollment in our clinical trials, including those being planned
or conducted in collaboration with partners. Such forward-looking
statements involve substantial risks and uncertainties that could cause
our future results, performance or achievements to differ significantly
from that expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in our clinical development programs for our drug candidates
and those of our partners, the corresponding development pathways of our
companion diagnostics, the timing of availability of data from our
clinical trials and the results, the initiation, enrollment and timing
of our planned clinical trials, actions by the FDA, the EMA or other
regulatory authorities regarding whether to approve drug applications
that may be filed, as well as their decisions regarding drug labeling,
reimbursement and pricing, and other matters that could affect the
development, availability or commercial potential of our drug candidates
or companion diagnostics. Clovis Oncology does not undertake to update
or revise any forward-looking statements. A further description of risks
and uncertainties can be found in Clovis Oncology’s filings with the
Securities and Exchange Commission, including its Annual Report on Form
10-K and its reports on Form 10-Q and Form 8-K.


Clovis Oncology
Clovis Investor Contacts:
Sussman, 303-625-5022
Burkart, 303-625-5023
Media Contacts: U.S.

Lisa Guiterman, 301-217-9353
Curran, 615-414-8668
Media Contact: EU

Ann Hughes, +44 (0) 7956 700 790